Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma

NCT04215016 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive

Interventions

BIOLOGICAL: Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells

Sponsor

Fujian Medical University